Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
An oral thrombin inhibitor. It belongs to the group of so-called non–vitamin K oral anticoagulants (NOACs) or direct anticoagulants.
Used in the prevention of venous thromboembolism in orthopedic surgery and atrial fibrillation.
Oral administration in a daily dose.
It is excreted in breastmilk in clinically insignificant amounts (Ayuk 2020 & 2016).
Its low oral bioavailability (EMA 2018, Blech 2008) hinders transfer to infant plasma via breastmilk, except in premature infants and the immediate neonatal period when there may be increased intestinal permeability.
It is the oral anticoagulant with the lowest excretion in breast milk (Daei 2021).